CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

berubicin (RTA 744) - CNS Pharma, WPD Pharma

May 25, 2023